Brii Bio takes hepatitis B treatment option

Brii Biosciences Limited, based in China and the U.S., has exercised its option to acquire exclusive development and commercialization rights for VIR-3434 in Greater China as part of its broader collaboration with Vir Biotechnology, Inc. 

VIR-3434, also known as BRII-877, is a broadly neutralizing monoclonal antibody targeting hepatitis B virus (HBV) that is currently in phase 2 development. This is Brii Bio’s second option exercise to a Vir infectious disease program with two remaining options still available to the company.

This move provides additional growth to Brii Bio’s clinical pipeline of therapeutic candidates for HBV. The company said adding another treatments provides more combination options to explore as part of its efforts to develop a functional cure for HBV.

“By exercising our option for VIR-3434 (BRII-877), Brii further solidifies our leading position in developing a functional cure for millions of HBV patients in China,” said Li Yan, chief medical officer of Brii Bio. 

“Recently announced data by Vir showed that BRII-835 (VIR-2218) and BRII-877 (VIR-3434) are additive to each other resulting in a robust reduction of hepatitis B surface antigen (HBsAg),

The post Brii Bio takes hepatitis B treatment option appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Source

About the Author: Biotech Today

You might like